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background: Although matrix metalloproteinase (MMP) and tissue inhibitors of MMP (TIMP) are dramatically changed in the early phase after AMI, 
there is little known about the correlation between these early changes and LV remodeling. We assessed the time course of MMP-2 and TIMP-2 and 
the correlation between MMP-2/TIMP-2 levels and left ventricular performance.
Methods: In 53 patients with successful reperfusion following AMI and 15 normal control subjects, serum levels of MMP-2 and TIMP-2 were 
measured on days1, 2, 3, 7 and 30 and at 6 and 12 months. Left ventriculography was performed on day1 and 30 and at 6 months after AMI and 
evaluated by the end-systolic volume index (ESVI), end-diastolic volume index (EDVI) and ejection fraction (EF). Left ventricular reverse remodeling 
(LVRR) was defined as a decrease of ESVI ≥15% at 6 months. 
results: MMP-2 levels were elevated on day 1 and then returned to the control value on day 3. From day 3, MMP-2 levels were transiently 
increased, with a peak on 6 months. The changes in MMP-2 from day 1 to 7 (delta-MMP-2) were correlated with the change in ESVI (delta-ESVI), 
EDVI (delta-EDVI) and EF (delta-EF) from day 30 to 6 months later (r=0.747, p<0.01, r=0.605, p<0.01 and r=-0.538, p<0.01, respectively). In LVRR 
group (n=18, 48.6%), patients had larger reductions of delta-MMP-2 (-332.55 ± 244.425 versus -60.83 ± 179.021, p<0.01), than those who 
without LVRR. A receiver operating curve predicting for LVRR by delta-MMP-2 had an area under the curve (AUC) of 0.791. The cut off value of delta-
MMP-2 with -158.5 was 91.7% sensitive and 76.9% specific in predicting LVRR. Stepwise multivariate logistic regression analysis indicated that the 
delta-MMP-2 was an independent predictor of LVRR (odds ratio 24.000, 95% confidence interval 2.060 to 279.624, p<0.05).
conclusions: MMP-2 levels increased shortly after AMI and the time-dependent changes of MMP-2 correlated with the worsening of ESVI, EDVI 
and EF. These results suggest that the constitutional release of MMP-2 relates to adverse left ventricular remodeling following AMI and attenuation of 
MMP-2 in early phase after AMI predicts reverse remodeling in chronic phase following AMI. 
